Clincosm LogoSign in Get a demo

Carcinoma, Non-Small-Cell Lung

Showing NaN - NaN of 53
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Augusta, Georgia
  • +40 more
Nov 29, 2023

Carcinoma, Non-small-Cell Lung Trial in New York, Fairfax (JNJ-86974680, Cetrelimab, Radiation Therapy)

Recruiting
  • Carcinoma, Non-small-Cell Lung
  • New York, New York
  • +1 more
Nov 8, 2023

NSCLC, Tumor Metastasis Trial in Worldwide (LY3537982, Pembrolizumab, Placebo)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Neoplasm Metastasis
  • Tucson, Arizona
  • +217 more
Nov 1, 2023

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Los Angeles, California
  • +83 more
Jan 31, 2023

NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Duarte, California
  • +228 more
Jan 31, 2023

NSCLC Trial in Worldwide (TAK-788)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Birmingham, Alabama
  • +56 more
Jan 23, 2023

NSCLC Trial in Worldwide (Sasanlimab Prefilled syringe, Encorafenib, Binimetinib)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sasanlimab Prefilled syringe
  • +5 more
  • Duarte, California
  • +96 more
Jan 18, 2023

NSCLC Trial in Worldwide (CC-486, Pembrolizumab, Placebo)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Glendale, Arizona
  • +33 more
Jan 12, 2023

NSCLC Trial in Worldwide (AZD7789)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Atlanta, Georgia
  • +8 more
Jan 12, 2023

Malignant Melanoma, NSCLC, Brain Tumors, Primary Trial in United States (PF-07284890, Binimetinib, Midazolam)

Recruiting
  • Malignant Melanoma
  • +4 more
  • Duarte, California
  • +71 more
Dec 29, 2022

NSCLC Trial in Worldwide (Selpercatinib, Placebo)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Santa Monica, California
  • +206 more
Dec 27, 2022

NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Tuscaloosa, Alabama
  • +260 more
Dec 16, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

NSCLC Trial in Boston, New York (MPDL3280A, Carboplatin, Nab-paclitaxel)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Boston, Massachusetts
  • +1 more
Oct 12, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Phoenix, Arizona
  • +303 more
Aug 17, 2022

Uterine Tumors, Uterine Cervical Tumors, Biliary Tract Tumors Trial in Worldwide (tucatinib, trastuzumab, fulvestrant)

Recruiting
  • Uterine Neoplasms
  • +5 more
  • Goodyear, Arizona
  • +63 more
Aug 15, 2022

NSCLC Trial in Worldwide (Durvalumab + SoC chemo, Placebo + SoC chemo)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Durvalumab + SoC chemotherapy
  • Placebo + SoC chemotherapy
  • Birmingham, Alabama
  • +147 more
Aug 1, 2022

NSCLC, Colorectal Neoplams, Endometrial Tumors Trial in Worldwide (LY3537982, Abemaciclib, Erlotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +4 more
  • Los Angeles, California
  • +21 more
Jul 22, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

NSCLC Trial in United States (XL647)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Gilroy, California
  • +9 more
May 9, 2022

NSCLC, Triple Negative Breast Tumors, Squamous Cell Carcinoma of Head and Neck Trial in United States (Pembrolizumab, TAK-676,

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • West Hollywood, California
  • +5 more
Mar 17, 2022

NSCLC Trial in Worldwide (nab-paclitaxel IV, CC-486, Duravalumab)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • nab-paclitaxel IV
  • +2 more
  • San Francisco, California
  • +33 more
Jan 24, 2022

Pralsetinib to Best Available Therapy in RET-Fusion Positive

Enrolling by invitation
  • RET-fusion Non Small Cell Lung Cancer
  • +16 more
    • New York, New York
    • +2 more
    Aug 9, 2021

    Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (PF-05082566, rituximab)

    Completed
    Has Results
    • Lymphoma, Non-Hodgkin
    • +6 more
    • Duarte, California
    • +41 more
    Mar 4, 2020